Overview

Psilocybin-Assisted Therapy for the Treatment of Cancer-Related Anxiety in Patients With Metastatic Cancer

Status:
Not yet recruiting

Trial end date:
2024-12-01

Target enrollment:

Participant gender:

Summary

This phase I/II trial tests the safety and side effects of psilocybin in combination with therapy for the treatment of patients with cancer for which no treatment is currently available. Psilocybin is a substance being studied for the treatment of anxiety or depression in patients with advanced cancer. It is taken from the mushroom psilocybe mexicana. Psilocybin acts on the brain to cause hallucinations (sights, sounds, smells, tastes, or touches that a person believes to be real but are not real). Giving psilocybin in combination with therapy may decrease anxiety in patients with metastatic cancer.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

University of Washington

Collaborator:

Steven and Alexandra Cohen Foundation

Treatments:

Psilocybin